Clodia Osipo - Publications

Molecular Biology Loyola University Chicago, Chicago, IL, United States 
Molecular Biology, Oncology

45 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Peiffer DS, Wyatt D, Zlobin A, Piracha A, Ng J, Dingwall AK, Albain KS, Osipo C. DAXX Suppresses Tumor-Initiating Cells in Estrogen Receptor-positive Breast Cancer following endocrine therapy. Cancer Research. PMID 31387918 DOI: 10.1158/0008-5472.CAN-19-1110  0.48
2018 Shah D, Wyatt D, Baker A, Simms P, Peiffer DS, Fernandez ML, Rakha EA, Green AR, Filipovic A, Miele L, Osipo C. Inhibition of HER2 Enriches for Jagged1-dependent Breast Cancer Stem Cells: Role for Membrane Jagged1. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29895705 DOI: 10.1158/1078-0432.CCR-17-1952  0.48
2018 Baker A, Wyatt D, Bocchetta M, Li J, Filipovic A, Green A, Peiffer DS, Fuqua S, Miele L, Albain KS, Osipo C. Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival. Oncogene. PMID 29743588 DOI: 10.1038/s41388-018-0251-y  0.48
2016 Nunes J, Zhang H, Angelopoulos N, Chhetri J, Osipo C, Grothey A, Stebbing J, Giamas G. ATG9A loss confers resistance to trastuzumab via c-Cbl mediated Her2 degradation. Oncotarget. PMID 27050377 DOI: 10.18632/oncotarget.8504  1
2016 Shah D, Osipo C. Cancer stem cells and HER2 positive breast cancer: The story so far Genes and Diseases. 3: 114-123. DOI: 10.1016/j.gendis.2016.02.002  1
2015 Pandya K, Wyatt D, Gallagher B, Bloodworth JC, Shah D, Baker A, Zlobin A, Pannuti A, Green AR, Ellis IO, Filipovic A, Sagert J, Rana A, Albain KS, Miele L, ... ... Osipo C, et al. PKCα Attenuates Jagged-1-mediated Notch Signaling in ErbB-2 positive Breast Cancer to Reverse Trastuzumab Resistance. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26350262 DOI: 10.1158/1078-0432.CCR-15-0179  1
2015 Das S, Sondarva G, Viswakarma N, Nair RS, Osipo C, Tzivion G, Rana B, Rana A. Human epidermal growth factor receptor 2 (HER2) impedes MLK3 kinase activity to support breast cancer cell survival Journal of Biological Chemistry. 290: 21705-21712. DOI: 10.1074/jbc.M115.655563  1
2014 Baker AT, Zlobin A, Osipo C. Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer. Frontiers in Oncology. 4: 360. PMID 25566499 DOI: 10.3389/fonc.2014.00360  1
2014 Weber CE, Kothari AN, Wai PY, Li NY, Driver J, Zapf MA, Franzen CA, Gupta GN, Osipo C, Zlobin A, Syn WK, Zhang J, Kuo PC, Mi Z. Osteopontin mediates an MZF1-TGF-β1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer. Oncogene. PMID 25531323 DOI: 10.1038/onc.2014.410  1
2014 Pandya K, Osipo C. Gene amplification of ErbB-2: From gene to therapy Medical Radiology. 63: 7-13. DOI: 10.1007/174_2014_1048  1
2013 Yun J, Pannuti A, Espinoza I, Zhu H, Hicks C, Zhu X, Caskey M, Rizzo P, D'Souza G, Backus K, Denning MF, Coon J, Sun M, Bresnick EH, Osipo C, et al. Crosstalk between PKCα and Notch-4 in endocrine-resistant breast cancer cells. Oncogenesis. 2: e60. PMID 23917222 DOI: 10.1038/oncsis.2013.26  1
2013 Olsauskas-Kuprys R, Zlobin A, Osipo C. Gamma secretase inhibitors of Notch signaling. Oncotargets and Therapy. 6: 943-55. PMID 23901284 DOI: 10.2147/OTT.S33766  1
2013 Speiser JJ, Erşahin C, Osipo C. The functional role of Notch signaling in triple-negative breast cancer. Vitamins and Hormones. 93: 277-306. PMID 23810012 DOI: 10.1016/B978-0-12-416673-8.00013-7  1
2013 Pekmezci M, Szpaderska A, Osipo C, Erşahin Ç. Evaluation of biomarkers in multifocal/multicentric invasive breast carcinomas. International Journal of Surgical Pathology. 21: 126-32. PMID 23204031 DOI: 10.1177/1066896912467370  1
2012 Pekmezci M, Szpaderska A, Osipo C, Erşahin C. The Effect of Cold Ischemia Time and/or Formalin Fixation on Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor-2 Results in Breast Carcinoma. Pathology Research International. 2012: 947041. PMID 22482085 DOI: 10.1155/2012/947041  1
2011 Pandya K, Meeke K, Clementz AG, Rogowski A, Roberts J, Miele L, Albain KS, Osipo C. Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence. British Journal of Cancer. 105: 796-806. PMID 21847123 DOI: 10.1038/bjc.2011.321  1
2011 Clementz AG, Rogowski A, Pandya K, Miele L, Osipo C. NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications. Breast Cancer Research : Bcr. 13: R63. PMID 21679465 DOI: 10.1186/bcr2900  1
2010 Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B, Miele L. Targeting Notch to target cancer stem cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 3141-52. PMID 20530696 DOI: 10.1158/1078-0432.CCR-09-2823  1
2010 Hao L, Rizzo P, Osipo C, Pannuti A, Wyatt D, Cheung LW, Sonenshein G, Osborne BA, Miele L. Notch-1 activates estrogen receptor-alpha-dependent transcription via IKKalpha in breast cancer cells. Oncogene. 29: 201-13. PMID 19838210 DOI: 10.1038/onc.2009.323  1
2009 Mehta K, Osipo C. Trastuzumab resistance: role for Notch signaling. Thescientificworldjournal. 9: 1438-48. PMID 20024517 DOI: 10.1100/tsw.2009.166  1
2009 Clementz AG, Osipo C. Notch versus the proteasome: what is the target of gamma-secretase inhibitor-I? Breast Cancer Research : Bcr. 11: 110. PMID 19849815 DOI: 10.1186/bcr2407  1
2009 Rizzo P, Osipo C, Pannuti A, Golde T, Osborne B, Miele L. Targeting Notch signaling cross-talk with estrogen receptor and ErbB-2 in breast cancer. Advances in Enzyme Regulation. 49: 134-41. PMID 19344631 DOI: 10.1016/j.advenzreg.2009.01.008  1
2008 Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L. Rational targeting of Notch signaling in cancer. Oncogene. 27: 5124-31. PMID 18758481 DOI: 10.1038/onc.2008.226  1
2008 Rizzo P, Miao H, D'Souza G, Osipo C, Song LL, Yun J, Zhao H, Mascarenhas J, Wyatt D, Antico G, Hao L, Yao K, Rajan P, Hicks C, Siziopikou K, et al. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Research. 68: 5226-35. PMID 18593923 DOI: 10.1158/0008-5472.CAN-07-5744  1
2008 Osipo C, Patel P, Rizzo P, Clementz AG, Hao L, Golde TE, Miele L. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene. 27: 5019-32. PMID 18469855 DOI: 10.1038/onc.2008.149  1
2008 Osipo C, Golde TE, Osborne BA, Miele LA. Off the beaten pathway: the complex cross talk between Notch and NF-kappaB. Laboratory Investigation; a Journal of Technical Methods and Pathology. 88: 11-7. PMID 18059366 DOI: 10.1038/labinvest.3700700  1
2008 Rizzo P, Miao H, D'Souza G, Osipo C, Song LL, Yun J, Zhao H, Mascarenhas J, Wyatt D, Antico G, Hao L, Yao K, Rajan P, Hicks C, Siziopikou K, et al. Cross-talk between Notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches (Cancer Research (July 1, 2008) 68 (5226-5235)) Cancer Research. 68: 7246. DOI: 10.1158/0008-5472.CAN-68-17-COR1  1
2007 Paunesku T, Vogt S, Lai B, Maser J, Stojićević N, Thurn KT, Osipo C, Liu H, Legnini D, Wang Z, Lee C, Woloschak GE. Intracellular distribution of TiO2-DNA oligonucleotide nanoconjugates directed to nucleolus and mitochondria indicates sequence specificity. Nano Letters. 7: 596-601. PMID 17274661 DOI: 10.1021/nl0624723  1
2007 Osipo C, Meeke K, Cheng D, Weichel A, Bertucci A, Liu H, Jordan VC. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer. International Journal of Oncology. 30: 509-20. PMID 17203234  1
2006 Liu H, Cheng D, Weichel AK, Osipo C, Wing LK, Chen B, Louis TE, Jordan VC. Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells. International Journal of Oncology. 29: 1237-46. PMID 17016657  1
2006 O'Regan RM, Osipo C, Ariazi E, Lee ES, Meeke K, Morris C, Bertucci A, Sarker MA, Grigg R, Jordan VC. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 2255-63. PMID 16609042 DOI: 10.1158/1078-0432.CCR-05-2584  1
2006 Osipo C, Miele L. Hedgehog signaling in hepatocellular carcinoma: novel therapeutic strategy targeting hedgehog signaling in HCC. Cancer Biology & Therapy. 5: 238-9. PMID 16552173  1
2005 Lewis JS, Meeke K, Osipo C, Ross EA, Kidawi N, Li T, Bell E, Chandel NS, Jordan VC. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. Journal of the National Cancer Institute. 97: 1746-59. PMID 16333030 DOI: 10.1093/jnci/dji400  1
2005 Levenson AS, Thurn KE, Simons LA, Veliceasa D, Jarrett J, Osipo C, Jordan VC, Volpert OV, Satcher RL, Gartenhaus RB. MCT-1 oncogene contributes to increased in vivo tumorigenicity of MCF7 cells by promotion of angiogenesis and inhibition of apoptosis. Cancer Research. 65: 10651-6. PMID 16322206 DOI: 10.1158/0008-5472.CAN-05-0845  1
2005 Jordan VC, Lewis JS, Osipo C, Cheng D. The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy. Breast (Edinburgh, Scotland). 14: 624-30. PMID 16202599 DOI: 10.1016/j.breast.2005.08.022  1
2005 Osipo C, Meeke K, Liu H, Cheng D, Lim S, Weichel A, Jordan VC. Trastuzumab therapy for tamoxifen-stimulated endometrial cancer. Cancer Research. 65: 8504-13. PMID 16166331 DOI: 10.1158/0008-5472.CAN-04-4107  1
2005 Lewis JS, Osipo C, Meeke K, Jordan VC. Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal Journal of Steroid Biochemistry and Molecular Biology. 94: 131-141. PMID 15862958 DOI: 10.1016/j.jsbmb.2004.12.032  1
2005 Osipo C, Gajdos C, Cheng D, Jordan VC. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy. The Journal of Steroid Biochemistry and Molecular Biology. 93: 249-56. PMID 15860267 DOI: 10.1016/j.jsbmb.2004.12.005  1
2004 Osipo C, Liu H, Meeke K, Jordan VC. The consequences of exhaustive antiestrogen therapy in breast cancer: estrogen-induced tumor cell death. Experimental Biology and Medicine (Maywood, N.J.). 229: 722-31. PMID 15337826  1
2004 Koeberle D, Perey L, Thuerlimann B, Jordan VC, Osipo C, Cheng D, Lewis JS. Re: Playing the old piano: Another tune for endocrine therapy (multiple letters) [2] Journal of the National Cancer Institute. 96: 555-557. PMID 15069120  1
2003 Jordan VC, Osipo C, Schafer JM, Fox JE, Cheng D, Liu H. Changing role of the oestrogen receptor in the life and death of breast cancer cells. Breast (Edinburgh, Scotland). 12: 432-41. PMID 14659118 DOI: 10.1016/S0960-9776(03)00149-8  1
2003 Osipo C, Gajdos C, Liu H, Chen B, Jordan VC. Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. Journal of the National Cancer Institute. 95: 1597-608. PMID 14600092  1
2003 Liu H, Lee ES, Gajdos C, Pearce ST, Chen B, Osipo C, Loweth J, McKian K, De Los Reyes A, Wing L, Jordan VC. Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo. Journal of the National Cancer Institute. 95: 1586-97. PMID 14600091  1
2002 Dardes RC, Schafer JM, Pearce ST, Osipo C, Chen B, Jordan VC. Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells Gynecologic Oncology. 85: 498-506. PMID 12051881 DOI: 10.1006/gyno.2002.6659  1
2001 Osipo C, Dorman S, Frankfater A. Loss of insulin-like growth factor II receptor expression promotes growth in cancer by increasing intracellular signaling from both IGF-I and insulin receptors Experimental Cell Research. 264: 388-396. PMID 11262195 DOI: 10.1006/excr.2000.5121  1
Show low-probability matches.